{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:14:12Z","timestamp":1792818852086,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00602","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:47:37Z","timestamp":1746726457000},"page":"e00602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment"],"prefix":"10.1016","volume":"22","author":[{"given":"Laura R.","family":"Naydovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Orthmann-Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde E.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurot.2025.e00602_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00602_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11910-012-0292-5","article-title":"Benign multiple sclerosis: does it exist?","volume":"12","author":"Correale","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00602_bib4","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/13524585221141964","article-title":"Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis","volume":"29","author":"Calvi","year":"2023","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib6","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00602_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"issue":"7638","key":"10.1016\/j.neurot.2025.e00602_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00602_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104789","article-title":"Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis","volume":"96","author":"Touil","year":"2023","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00602_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3681","article-title":"Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation","volume":"20","author":"Mayo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00602_bib11","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3389\/fimmu.2017.02012","article-title":"NLR-dependent regulation of inflammation in multiple sclerosis","volume":"8","author":"Gharagozloo","year":"2018","journal-title":"Front Immunol"},{"issue":"Pt 4","key":"10.1016\/j.neurot.2025.e00602_bib12","first-page":"1089","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"Pt 11","key":"10.1016\/j.neurot.2025.e00602_bib13","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00602_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib16","first-page":"1083","article-title":"Continuum (Minneap Minn)","volume":"28","author":"Amezcua","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00602_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000001269","article-title":"Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations","volume":"37","author":"Kr\u00e4mer","year":"2024","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","article-title":"Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges","volume":"23","author":"Chataway","year":"2024","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00602_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00602_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00602_bib22","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2025.e00602_bib23","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1212\/NXI.0000000000000431","article-title":"Proinflammatory Bcell profile in the early phases of MS predicts an active disease","volume":"5","author":"Guerrier","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurot.2025.e00602_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3389\/fimmu.2017.00775","article-title":"TLR7\/TLR9- and B Cell receptor-signaling crosstalk: promotion of potentially dangerous B cells","volume":"8","author":"Suthers","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nri3190","article-title":"Integration of B cell responses through Toll-like receptors and antigen receptors","volume":"12","author":"Rawlings","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00602_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00602_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"issue":"6409","key":"10.1016\/j.neurot.2025.e00602_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00602_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/bies.950181009","article-title":"X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease","volume":"18","author":"Mattsson","year":"1996","journal-title":"Bioessays"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-024-02730-0","article-title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair","volume":"147","author":"Geladaris","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00602_bib32","doi-asserted-by":"crossref","first-page":"E1738","DOI":"10.1073\/pnas.1525528113","article-title":"New tools for studying microglia in the mouse and human CNS","volume":"113","author":"Bennett","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00602_bib33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00602_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00602_bib36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.drudis.2014.03.028","article-title":"Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"19","author":"Whang","year":"2014","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00602_bib37","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/emboj\/17.7.1973","article-title":"Btk\/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation","volume":"17","author":"Fluckiger","year":"1998","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00602_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expet Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","article-title":"BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy","volume":"143","author":"Li","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2025.e00602_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-065X.2010.00963.x","article-title":"Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors","volume":"238","author":"Kondo","year":"2010","journal-title":"Immunol Rev"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00602_bib43","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1074\/jbc.M508892200","article-title":"MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction","volume":"281","author":"Gray","year":"2006","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.neurot.2025.e00602_bib44","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","article-title":"Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis","volume":"181","author":"Jongstra-Bilen","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085834","article-title":"Btk regulates macrophage polarization in response to lipopolysaccharide","volume":"9","author":"N\u00ed Gabhann","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00602_bib47","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.187.8.1235","article-title":"Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production","volume":"187","author":"Hata","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurot.2025.e00602_bib48","article-title":"BTK and MMP9 regulate NLRP3 inflammasome-dependent cytokine and NET responses in primary neutrophils","author":"Leal","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.neurot.2025.e00602_bib49","first-page":"181","article-title":"Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients","volume":"13","author":"Amoras","year":"2003","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/ar2590","article-title":"Increased expression of FcgammaRI\/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus","volume":"11","author":"Li","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175961","article-title":"The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement","volume":"12","author":"Cavaliere","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00602_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176460","article-title":"Phenotype, function, and differentiation potential of human monocyte subsets","volume":"12","author":"Boyette","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11481-019-09839-0","article-title":"Inhibition of bruton's tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer's disease","volume":"14","author":"Keaney","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00602_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fncel.2013.00045","article-title":"Origin and differentiation of microglia","volume":"7","author":"Ginhoux","year":"2013","journal-title":"Front Cell Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00602_bib55","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/nn2014","article-title":"Local self-renewal can sustain CNS microglia maintenance and function throughout adult life","volume":"10","author":"Ajami","year":"2007","journal-title":"Nat Neurosci"},{"issue":"6005","key":"10.1016\/j.neurot.2025.e00602_bib56","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00602_bib57","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.neuron.2018.05.014","article-title":"A combination of ontogeny and CNS environment establishes microglial identity","volume":"98","author":"Bennett","year":"2018","journal-title":"Neuron"},{"issue":"6344","key":"10.1016\/j.neurot.2025.e00602_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3222","article-title":"An environment-dependent transcriptional network specifies human microglia identity","volume":"356","author":"Gosselin","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00602_bib59","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/brain\/awab231","article-title":"MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response","volume":"144","author":"Pellerin","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12974-024-03187-4","article-title":"Bruton's tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia","volume":"21","author":"Xu","year":"2024","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1006\/bbrc.1996.1112","article-title":"A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage","volume":"224","author":"Imai","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.neurot.2025.e00602_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1264128","article-title":"Expression of Bruton's tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination","volume":"14","author":"Elkjaer","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00602_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13240","article-title":"The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis","volume":"34","author":"Steinmaurer","year":"2024","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00602_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton's tyrosine kinase inhibition promotes myelin repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"key":"10.1016\/j.neurot.2025.e00602_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-function relationships of covalent and non-covalent BTK inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00602_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00602_bib67","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/cts.13108","article-title":"Evobrutinib, a covalent Bruton\u2019s tyrosine kinase inhibitor: mass balance, elimination route, and metabolism in healthy participants","volume":"14","author":"Scheible","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00602_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of the Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R&D"},{"issue":"25","key":"10.1016\/j.neurot.2025.e00602_bib69","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-Controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"issue":"4-5","key":"10.1016\/j.neurot.2025.e00602_bib70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00602_bib71","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00602_bib72","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/1352458512450354","article-title":"Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis","volume":"18","author":"Miller","year":"2012","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00602_bib73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00602_bib74","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1007\/s00415-021-10455-3","article-title":"Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study","volume":"268","author":"Bucello","year":"2021","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00602_bib75","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1007\/s00415-022-11118-7","article-title":"Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study","volume":"269","author":"Zhang","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00602_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2019.03.022","article-title":"Teriflunomide real-world evidence: global differences in the phase 4 Teri-PRO study","volume":"31","author":"Coyle","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00602_bib77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00602_bib78","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","article-title":"BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial","volume":"8","author":"Kappos","year":"2009","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00602_bib79","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00602_bib80","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00602_bib81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cts.13162","article-title":"Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)","volume":"15","author":"Owens","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00602_bib82","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00602_bib83","article-title":"Safety and clinical efficacy outcomes from the long-term extension study of tolebrutinib in participants with relapsing multiple sclerosis [Internet]","year":"2023","journal-title":"Sanofi Congress"},{"key":"10.1016\/j.neurot.2025.e00602_bib84","series-title":"ACTRIMS 2024: tolebrutinib fails to eliminate PRLs in small trial","author":"Maia","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00602_bib85","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00602_bib86","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"8","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00602_bib87","article-title":"Ectrims 2024: tolebrutinib may target smoldering inflammation in MS [Internet]","author":"Lobo","year":"2024","journal-title":"Multiple Sclerosis News Today"},{"key":"10.1016\/j.neurot.2025.e00602_bib88","series-title":"Patient enrollment of phase III tolebrutinib trials paused in the U.S. News release","year":"2022"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00602_bib89","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton\u2019s tyrosine kinase inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurot.2025.e00602_bib91","series-title":"Presented at: 2024 congress of the European committee for treatment and research in multiple sclerosis (ECTRIMS)","article-title":"Fenebrutinib maintains low disease activity in patients with relapsing multiple sclerosis: results from the Phase 2 FENopta trial [Poster]","author":"Bar-Or","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00602_bib92","series-title":"A study to evaluate the efficacy, safety, and tolerability of fenebrutinib in adults with relapsing multiple sclerosis (FENHANCE 1)","year":"2020"},{"key":"10.1016\/j.neurot.2025.e00602_bib93","series-title":"A study to evaluate the efficacy, safety, and tolerability of fenebrutinib in adults with relapsing multiple sclerosis (FENHANCE 2)","year":"2020"},{"key":"10.1016\/j.neurot.2025.e00602_bib94","series-title":"A study to evaluate the efficacy, safety, and tolerability of fenebrutinib compared with teriflunomide in relapsing multiple sclerosis (FENTREPID)","year":"2020"},{"key":"10.1016\/j.neurot.2025.e00602_bib95","article-title":"Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis","year":"2024","journal-title":"GlobeNewswire"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00602_bib96","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00602_bib97","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00602_bib98","series-title":"A study to assess efficacy and safety of remibrutinib in relapsing multiple sclerosis (REMODEL II)","year":"2021"},{"key":"10.1016\/j.neurot.2025.e00602_bib99","series-title":"A study to assess efficacy and safety of remibrutinib in relapsing multiple sclerosis (REMODEL I)","year":"2021"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00602_bib100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph15070779","article-title":"Novel therapies to address unmet needs in ITP","volume":"15","author":"Mingot-Castellano","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neurot.2025.e00602_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neurot.2025.e00602_bib102","series-title":"A study to evaluate the efficacy and safety of orelabrutinib in relapsing-remitting multiple sclerosis","year":"2021"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00602_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1295","article-title":"Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells","volume":"10","author":"Bame","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.neurot.2025.e00602_bib104","series-title":"A study to assess safety and tolerability of BIIB091 in participants with relapsing forms of multiple sclerosis","year":"2023"},{"issue":"6682","key":"10.1016\/j.neurot.2025.e00602_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"suppl 1","key":"10.1016\/j.neurot.2025.e00602_bib106","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2025.e00602_bib107","article-title":"BTK inhibitor orelabrutinib shows promising efficacy in phase 2 study of relapsing-remitting multiple sclerosis","author":"Meglio","year":"2025","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:04:31Z","timestamp":1755090271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000807"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00602","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00602"}}